To watch the video series component of this episode, click here. 

1:12 Suboptimal Response
6:42 Treatment Strategy
11:22 Response to New Therapies
14:12 Imaging for Monitoring
18:42 Role of Ang-2

Age-Related Macular Degeneration

age-related macular degeneration condition center page is a comprehensive resource for clinical news and insights on retina disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for patients with AMD.

Diabetic Macular Edema

The HCPLive diabetic macular edema page is a comprehensive resource for clinical news and insights on DME. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the leading cause of blindness, and more.

MedCasts

Medcast Podcasts

Cleveland Clinic

HCPLive® Strategic Alliance Partnerships feature insights, opinions, and perspectives delivered from experts at our healthcare system and institution partnerships.

Strategic Alliance Partnership

Recent advancements in the management of lung cancer brain metastases have significantly improved patient outcomes. The integration of novel therapies, including targeted treatments and immunotherapy, has shown promise in enhancing response rates and prolonging survival. Imaging techniques play a crucial role in monitoring treatment efficacy and disease progression. Angiopoietin-2 (Ang-2) has emerged as a potential biomarker for assessing treatment response and guiding therapeutic decisions. These developments underscore the importance of a multidisciplinary approach in optimizing treatment strategies and improving the quality of life for patients with brain metastases from lung cancer.

A panel of ophthalmologists discuss strategies for managing AMD and DME patients who exhibit suboptimal responses to their current anti-VEGF therapy.

Addressing Suboptimal Anti-VEGF Response in Neovascular AMD and DME